CD29和EGFR在乳腺癌中的表达及临床意义(4)
[13] Takada M，Nakagawa K.Role of EGFR monoclonal antibodies in the management of non-small cell lung cancer[J].Curr Cancer Drug Targets，2015，15(9)：792-802.
[14] Galak Chandarlapaty S.Molecular pathways：Her-3 targeted therapy[J].Clin Cancer Res，2014，20(7)：1410-1416.
[15] Kazmierczak P M，Todica A，Gildehaus F J，et al.68Ga-TRAP-(RGD)3 hybrid imaging for the in vivo monitoring of αv?3-integrin expression as biomarker of anti-angiogenic therapy effects in experimental breast cancer[J].PLoS One，2016，11(12)：168-180.
[16] Nozoe T.Immunohistochemical expression of epidemal growth factor receptor in breast cancer[J].Breast Cancer，2011，18(1)：37-41.
[17] Bernardes N，Abreu S，Carvalho F A，et al.Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion[J].Cell Cycle，2016，15(11)：1415-1424.
[18] Zhu X，Zhu Y J，Kim D W，et al.Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer[J].Am J Cancer Res，2014，4(6)：776-788.
[19] Seguin L，Kato S，Franovic A，et al.An integrin β3-KRAS-Ral B complex drives tumour stemness and resistance to EGFR inhibition[J].Nat Cell Biol，2014，16(5)：457-468.
[20] Brown W S，Wendt M K.Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy：an inflammatory situation[J].Breast Cancer Res，2014，16(5)：448-456., http://www.100md.com(邱立 柳玉红 龚静青 汪春福)
[14] Galak Chandarlapaty S.Molecular pathways：Her-3 targeted therapy[J].Clin Cancer Res，2014，20(7)：1410-1416.
[15] Kazmierczak P M，Todica A，Gildehaus F J，et al.68Ga-TRAP-(RGD)3 hybrid imaging for the in vivo monitoring of αv?3-integrin expression as biomarker of anti-angiogenic therapy effects in experimental breast cancer[J].PLoS One，2016，11(12)：168-180.
[16] Nozoe T.Immunohistochemical expression of epidemal growth factor receptor in breast cancer[J].Breast Cancer，2011，18(1)：37-41.
[17] Bernardes N，Abreu S，Carvalho F A，et al.Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion[J].Cell Cycle，2016，15(11)：1415-1424.
[18] Zhu X，Zhu Y J，Kim D W，et al.Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer[J].Am J Cancer Res，2014，4(6)：776-788.
[19] Seguin L，Kato S，Franovic A，et al.An integrin β3-KRAS-Ral B complex drives tumour stemness and resistance to EGFR inhibition[J].Nat Cell Biol，2014，16(5)：457-468.
[20] Brown W S，Wendt M K.Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy：an inflammatory situation[J].Breast Cancer Res，2014，16(5)：448-456., http://www.100md.com(邱立 柳玉红 龚静青 汪春福)